Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide and recurrent aphthous stomatitis: a follow-up study

J M Bonnetblanc1, C Royer, C Bedane

  • 1Department of Dermatology, CHRU Dupuytren, Limoges, France.

Dermatology (Basel, Switzerland)
|January 1, 1996
PubMed
Summary

A minority of patients with recurrent aphthous stomatitis (RAS) can stop thalidomide treatment. Some patients achieve remission with low thalidomide doses, potentially reducing severe side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

French national protocol for diagnosis and management of pemphigoid gestationis.

Annales de dermatologie et de venereologie·2026
Same author

Prevalence of sleep disorders in patients with bullous pemphigoid.

Annales de dermatologie et de venereologie·2026
Same author

Alteration history of aluminum-rich rocks at Jezero crater, Mars.

Communications earth & environment·2025
Same author

Intense alteration on early Mars revealed by high-aluminum rocks at Jezero crater.

Communications earth & environment·2024
Same author

Radiation-induced alteration of apatite on the surface of Mars: first in situ observations with SuperCam Raman onboard Perseverance.

Scientific reports·2024
Same author

Evolution of rituximab use over time in moderate-to-severe pemphigus: A two-centre retrospective study.

Annales de dermatologie et de venereologie·2024

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Thalidomide is a treatment for recurrent aphthous stomatitis (RAS).
  • Previous reports suggested remission but lacked evaluation.
  • The efficacy of dose reduction or cessation was not well-studied.

Purpose of the Study:

  • To determine the number of patients with RAS who could discontinue or reduce their thalidomide dosage.
  • To assess long-term outcomes of thalidomide treatment in RAS patients.

Main Methods:

  • Retrospective study of 25 patients with RAS treated with thalidomide.
  • Minimum follow-up duration of 1 year.
  • Evaluation of treatment cessation, dose reduction, and response to standard dosage.

Main Results:

  • Six patients (24%) successfully stopped thalidomide, experiencing only minor aphthae.
  • Ten patients (40%) required minimal daily thalidomide doses for remission.
  • Seven patients (28%) did not respond to 100 mg daily thalidomide.
  • One patient had early side effects, and one was lost to follow-up.

Conclusions:

  • A minority of RAS patients can stop thalidomide therapy.
  • Low-dose thalidomide can maintain remission in some patients.
  • Dose reduction may mitigate severe side effects associated with thalidomide treatment.

Related Experiment Videos